Drugs / QL1209
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04629846 | Nov 2020 → Aug 2022 | breast cancer | Qilu Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QL1209 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04629846 ↗ |
| Modality | Monoclonal antibody | “Recombinant anti-HER-2 domain Ⅱ humanized monoclonal antibody injection” NCT04629846 ↗ |
| Route | Intravenous | “QL1209 IV infusion” NCT04629846 ↗ |